Musculoskeletal
Degenerative Disc Disease
1
Pipeline Programs↗
8
Active Trials↗
6
Companies Involved↗
Degenerative Disc Disease is an early-stage landscape with 1 program across 6 companies. The most active players are Angitia Biopharmaceuticals, Eli Lilly, Biosplice Therapeutics, Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31
Approved
No programs
Analysis
Trial Status
17
clinical trials
Completed5 · 29%
Recruiting4 · 24%
Terminated3 · 18%
Active, not recruiting3 · 18%
Unknown status1 · 6%
Not yet recruiting1 · 6%
Clinical Trials
Trial Activity
17 trials
A Multi-Center, Prospective, Historically Controlled Pivotal Trial Comparing the Safety and Effectiveness of the Synergy Disc to Anterior Cervical Discectomy and Fusion in Patients With Two-Level Symptomatic Cervical Degenerative Disc Disease (DDD)
Active, not recruiting·—·Preclinical·NCT05740176·200 enrolled
Minimally Invasive Isolated Decompression From the Posterior Approach for Degenerative Spinal Stenosis of the Cervical Spine
Active, not recruiting·N.N. Priorov National Medical Research Center of Traumatology and Orthopedics·Preclinical·NCT06995300·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)